Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Clinical and immunological outcomes after randomized trial of baked milk oral immunotherapy for milk allergy
Jennifer A. Dantzer, … , Bjoern Peters, Robert A. Wood
Jennifer A. Dantzer, … , Bjoern Peters, Robert A. Wood
Published January 9, 2025
Citation Information: JCI Insight. 2025;10(1):e184301. https://doi.org/10.1172/jci.insight.184301.
View: Text | PDF
Clinical Research and Public Health Clinical trials Immunology

Clinical and immunological outcomes after randomized trial of baked milk oral immunotherapy for milk allergy

  • Text
  • PDF
Abstract

BACKGROUND Cow’s milk (CM) allergy is the most common food allergy in young children. Treatment with oral immunotherapy (OIT) has shown efficacy, but high rates of adverse reactions. The aim of this study was to determine whether baked milk OIT (BMOIT) could reduce adverse reactions while still inducing desensitization, and to identify immunological correlates of successful BMOIT.METHODS This phase II, randomized trial evaluated the safety and efficacy of BMOIT in milk-allergic children 3–18 years old. After the initial placebo-controlled first year of treatment, placebo-treated participants crossed over to active BMOIT. Double-blind, placebo-controlled oral food challenges (OFCs) were conducted with BM after year 1 and to both BM and unheated milk (UM) after year 2. IgG and IgE antibodies were measured along with CM-specific (CM+) CD4+ memory T cell populations, profiled using flow cytometry and scRNA-Seq.RESULTS Twenty-one of 30 (70%) reached the primary endpoint of tolerating 4044 mg of BM protein at month 24, and 11 of 30 tolerated 2000 mg or more of UM protein. Dosing symptoms were common, but more than 98% were mild, with no severe reactions. Immunological changes associated with desensitization included increased CM IgG4, CM+ FOXP3+ cells, and Tregs and corresponding decreases in CM IgE, CM+ Th2A cells, and CD154+ cells. T cell and antibody measurements were combined to build a model that predicted UM OFC outcomes.CONCLUSION BMOIT was well tolerated and induced desensitization to BM and UM. This desensitization corresponded to redistribution within antigen-specific antibody and T cell compartments that provided insight into the mechanistic changes that occur with OIT treatment.TRIAL REGISTRATION ClinicalTrials.gov NCT03462030.FUNDING: Myra Reinhardt Family Foundation (grant number 128388), NIH/NIAID (U19AI135731, T32AI125179, S10OD025052)

Authors

Jennifer A. Dantzer, Sloan A. Lewis, Kevin J. Psoter, Aaron Sutherland, April Frazier, Eve Richardson, Synaida Maiche, Gregory Seumois, Bjoern Peters, Robert A. Wood

×

Figure 9

Combined classification of OFC outcome.

Options: View larger image (or click on image) Download as PowerPoint
Combined classification of OFC outcome.
(A) Box-and-whisker plots showin...
(A) Box-and-whisker plots showing the area under the curve (AUC) values for each CV fold of overall best model selected (highest mean) for each set of features and outcome. Feature time point, outcome type, best model, and mean AUC across folds are indicated on the bottom. (B) Feature importance coefficients per fold for each feature in the best performing model from E (24-month unheated milk oral food challenge [UMOFC]). (C) Logistic model equation to predict UMOFC outcome. In the box-and-whisker plots, the box represents the middle 50% of data, with the bottom and top lines of the box representing the 1st and 3rd quarterlies, respectively. The line in the box represents the median. The whiskers extend to the minimum and maximum values. Outliers are indicated with dots.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts